(154) Safety and Efficacy of Platelet-rich Plasma Injection for the Treatment of Erectile Dysfunction; A Randomized Prospective Study

A Ragheb,M Fahmy,A Lotfy,A Elmarakby

DOI: https://doi.org/10.1093/jsxmed/qdae001.145

2024-02-07

The Journal of Sexual Medicine

Abstract:Introduction Platelet-rich plasma (PRP) intracorporeal injection is one of the popular regenerative therapies that has been gaining much interest in recent years as an adjunct or alternative treatment for erectile dysfunction (ED). Nevertheless, scientific evidence to support its clinical efficacy remains controversial. Objective The aim of this study was to evaluate the safety and efficacy of PRP injections for the treatment of ED. Methods A prospective, randomized, double-blinded, placebo-controlled, interventional clinical study was conducted on 52 subjects. Patients were randomized into two groups: the PRP group (n=26) and the placebo (saline) group (n=26). Each participant received three sessions (at two-week intervals) of PRP or saline injections according to his assigned group. International index of erectile function-5 (IIEF-5) scores and safety-related observations were collected during the 1st, 3rd, and 6th months of follow-up. Results The median age and ED duration were statistically comparable for both groups, 52.2 versus 52.5 years and 12.87 versus 11.8, respectively (P = 0.285). With regards to the efficacy of PRP, there were no statistically significant differences between both groups after 1, 3, and 6 months of treatment. After 1 month of treatment, the mean IIEF-5 score for the PRP group was 16.12 ± 1.25 versus 15.99 ± 1.21 for the placebo group (P = 0.683). After 3 months, the IIEF-5 score for the PRP group was 16.44 ± 1.17 compared to 16.31 ± 1.06 for the placebo group (P = 0.653). Also after 6 months, the IIEF-5 score for the PRP group was 16.35 ± 1.45 close to 16.23 ± 1.19 for the placebo group (P = 0.727). No transient hemorrhagic adverse events (hematuria, local petechial bleeding, or ecchymosis) or other side effects were reported during the injection and follow-up period for both groups. Conclusions The results of this trial suggest that although the treatment of ED with 3 injections of intracavernosal PRP separated by two-week intervals may be safe, it is not more effective than a placebo injection. Disclosure No.

urology & nephrology

What problem does this paper attempt to address?

This paper aims to evaluate the safety and efficacy of platelet - rich plasma (PRP) injection in the treatment of erectile dysfunction (ED). Although PRP, as a regenerative therapy, has received extensive attention in recent years and is one of the adjuvant or alternative treatment methods for ED, the scientific evidence for its clinical efficacy remains controversial. Therefore, researchers conducted a prospective, randomized, double - blind, placebo - controlled interventional clinical trial to specifically evaluate the effect of PRP injection in the treatment of ED.

### Research Background
- **Objective**: To evaluate the safety and efficacy of PRP injection in the treatment of ED.
- **Methods**: The study selected 52 subjects and randomly divided them into two groups, with 26 people in each group. One group received PRP injection (PRP group), and the other group received normal saline injection (placebo group). Each participant received three injections according to the grouping situation (with an interval of two weeks each time). Researchers collected the International Index of Erectile Function - 5 (IIEF - 5) scores and safety - related observation data during the follow - up periods of the 1st month, 3rd month, and 6th month.
- **Results**:
- There were no statistically significant differences in the median age and ED duration between the two groups of subjects, which were 52.2 years vs. 52.5 years and 12.87 years vs. 11.8 years respectively (\(P = 0.285\)).
- At 1 month, 3 months, and 6 months after treatment, there were no statistically significant differences in IIEF - 5 scores between the PRP group and the placebo group. Specifically:
- One month after treatment, the average IIEF - 5 score in the PRP group was \(16.12 \pm 1.25\), and that in the placebo group was \(15.99 \pm 1.21\) (\(P = 0.683\)).
- Three months after treatment, the average IIEF - 5 score in the PRP group was \(16.44 \pm 1.17\), and that in the placebo group was \(16.31 \pm 1.06\) (\(P = 0.653\)).
- Six months after treatment, the average IIEF - 5 score in the PRP group was \(16.35 \pm 1.45\), and that in the placebo group was \(16.23 \pm 1.19\) (\(P = 0.727\)).
- During the entire injection and follow - up periods, neither group reported any transient bleeding adverse events (such as hematuria, local petechial bleeding or ecchymosis) or other side effects.
- **Conclusion**: The test results show that although intracorporeal penile PRP injection for ED treatment three times at an interval of two weeks may be safe, its effect is no more effective than placebo injection.

This study provides scientific evidence regarding PRP injection in the treatment of ED, indicating that although PRP injection may be a safe treatment method, it is not superior to placebo in improving the erectile function of ED patients. This provides an important reference for future research and clinical applications.